- Home
- ONL vs DMAC Comparison
ONL vs DMAC Comparison
Compare ONL & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONL
- DMAC
- Stock Information
- Founded
- ONL 2021
- DMAC 2000
- Country
- ONL United States
- DMAC United States
- Employees
- ONL N/A
- DMAC N/A
- Industry
- ONL Real Estate Investment Trusts
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ONL Real Estate
- DMAC Health Care
- Exchange
- ONL Nasdaq
- DMAC Nasdaq
- Market Cap
- ONL 210.4M
- DMAC 224.6M
- IPO Year
- ONL N/A
- DMAC N/A
- Fundamental
- Price
- ONL $4.05
- DMAC $5.80
- Analyst Decision
- ONL Hold
- DMAC Strong Buy
- Analyst Count
- ONL 1
- DMAC 3
- Target Price
- ONL N/A
- DMAC $7.00
- AVG Volume (30 Days)
- ONL 391.1K
- DMAC 100.7K
- Earning Date
- ONL 03-05-2025
- DMAC 03-18-2025
- Dividend Yield
- ONL 9.83%
- DMAC N/A
- EPS Growth
- ONL N/A
- DMAC N/A
- EPS
- ONL N/A
- DMAC N/A
- Revenue
- ONL $169,644,000.00
- DMAC N/A
- Revenue This Year
- ONL N/A
- DMAC N/A
- Revenue Next Year
- ONL N/A
- DMAC N/A
- P/E Ratio
- ONL N/A
- DMAC N/A
- Revenue Growth
- ONL N/A
- DMAC N/A
- 52 Week Low
- ONL $3.01
- DMAC $2.14
- 52 Week High
- ONL $5.48
- DMAC $6.41
- Technical
- Relative Strength Index (RSI)
- ONL 60.83
- DMAC 58.22
- Support Level
- ONL $3.86
- DMAC $5.25
- Resistance Level
- ONL $4.07
- DMAC $5.85
- Average True Range (ATR)
- ONL 0.12
- DMAC 0.39
- MACD
- ONL 0.03
- DMAC 0.01
- Stochastic Oscillator
- ONL 98.36
- DMAC 73.02
About ONL Orion Office REIT Inc.
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.